Perspectives
Open Access
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19
Meagan L. Adamsick, Ronak G. Gandhi, Monique R. Bidell, Ramy H. Elshaboury, Roby P. Bhattacharyya, Arthur Y. Kim, Sagar Nigwekar, Eugene P. Rhee and Meghan E. Sise
JASN July 2020, 31 (7) 1384-1386; DOI: https://doi.org/10.1681/ASN.2020050589
Meagan L. Adamsick
1Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
Ronak G. Gandhi
1Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
Monique R. Bidell
1Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
Ramy H. Elshaboury
1Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
Roby P. Bhattacharyya
2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
Arthur Y. Kim
2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
Sagar Nigwekar
3Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
Eugene P. Rhee
3Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
Meghan E. Sise
3Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
In this issue
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19
Meagan L. Adamsick, Ronak G. Gandhi, Monique R. Bidell, Ramy H. Elshaboury, Roby P. Bhattacharyya, Arthur Y. Kim, Sagar Nigwekar, Eugene P. Rhee, Meghan E. Sise
JASN Jul 2020, 31 (7) 1384-1386; DOI: 10.1681/ASN.2020050589
Jump to section
More in this TOC Section
Cited By...
- Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 Therapy
- Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir
- COVID-19 and AKI: Where Do We Stand?
- Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019
- The efficacy and safety of remdesivir in the treatment of patients with COVID-19: a systematic review and meta-analysis
- Outcomes of COVID-19 among Patients with End Stage Renal Disease on Remdesivir
- Remdesivir in COVID-19 Patients with Impaired Renal Function
- New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
- Management of COVID-19 in special populations with kidney disease
- Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent hemodialysis
- Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study